2018 (4th) International Symposium on Next-Generation CAR & TCR-T Cells is organized by Bioon and will be held from Nov 23 - 24, 2018 at Hope Hotel Shanghai, Shanghai, China.
Chimeric antigen receptors (CARs) are engineered receptors that combine a new specificity with an immune cell to target cancer cells. Typically, these receptors graft the specificity of a monoclonal antibody onto a T cell. The receptors are called chimeric because they are fused of parts from different sources. CAR-T cells are a new type of treatment that uses living cells that have been transformed.
These T-cells are genetically engineered to express an artificial T cell receptor, through which they are targeted to disease-related antigens. This process is MHC independent and thus the targeting efficiency is greatly increased. Progress need to be made in treatment of solid tumors. Besides, CAR-T cells are developed to be specific to an antigen expressed on a tumor that is not expressed on healthy cells. Apart from these, novel cellular immunotherapies like TCR-T and CAR-NK are under development.
Additional details will be posted as soon as they are available.
|Registration Type||Due Date||Price|
|Standard Ticket||22 Nov,2018||USD 1200.00|
|Registration Type||End Date||Price|
|Early Bird Ticket||26 Oct,2018||USD 600.00|
|Preferential Ticket||09 Nov,2018||USD 1000.00|